Sales rose 4% and were 2% ahead of expectation on strong sales from core drugs and promising results from new treatments.
The drug company maintained its 2017 guidance, but sales of two of its key drugs registered disappointing results, and shares were down in after-hours trading 3%.
Akebia after the market close on Tuesday announced an expanded partnership with Japan's Otsuka Pharmaceuticals to develop and market its anemia pill Vadadustat in Europe, China and other territories.
Fresenius announced a deal to buy U.S. generic drugmaker Akorn Inc for $4.75 billion, or $34 per share.
Estimates for erenumab annual sales run as high as $2.3 billion.
Biogen's new spine disease drug outperformed expectations during its commercial debut.
Fresenius announced a deal to buy U.S. generic drugmaker Akorn Inc for $4.75 billion and the biosimilars unit of German peer Merck KGaA.